Morgan Stanley downgraded Amicus (FOLD) to Equal Weight from Overweight with a price target of $12, down from $17. Over the last tyear, the company has executed well commercially, met its goals financially by achieving profitability for 2024, an settled its Galafold patent litigation with Teva (TEVA), the analyst tells investors in a research note. The firm continues to believe that Amicus is well-positioned, but thinks expectations have increased with the company’s progress, which are now largely priced into shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD: